Stockreport

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions [Yahoo! Finance]

Scinai Immunotherapeutics Ltd. - American Depositary Shares  (SCNI) 
PDF Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) PC111 has already [Read more]